Sign in
Taking peoplePhase 1/2

Testing EN001 for Charcot-Marie-Tooth Disease Type 1A

Tests EN001 for safety and effect in adults with Charcot-Marie-Tooth disease type 1A.

Key facts

Who runs it
ENCell
Where
South Korea3 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)
Status
Recruiting
Phase
Phase 1/2
People taking part
27 people, planned
Started
30 May 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • EN001
  • EN001 Placebo
Record updated
26 May 2026

Who can take part

The trial is looking for adults with Charcot-Marie-Tooth disease type 1A (CMT1A), confirmed by a genetic test. It tests the drug EN001 against a placebo (dummy drug).

Age
19 years or older
Sex
Men and women
Disease stage
CMT1A with a CMT Neuropathy Score version 2 (CMTNSv2) from 2 to 20. People must have muscle weakness from trouble lifting the foot upward.
Earlier treatment
People cannot join if they ever had cell therapy or gene therapy. They cannot join if they had immunosuppressants, chemotherapy or radiation therapy within 12 weeks before screening. They cannot join if they had another trial drug or device within 4 weeks before screening. Some nerve-damaging drugs are also not allowed before screening.
Biomarker or test result
Genetic diagnosis of CMT1A type.
Main reasons for not taking part
  • Other nerve or muscle diseases, or type 1 or type 2 diabetes
  • Ankle stiffness (contracture) or leg bone or joint surgery within 24 weeks before screening
  • Stroke or heart attack within 48 weeks, or cancer within 240 weeks before screening
  • Metal implants such as a heart pacemaker, nerve stimulator or cochlear implant
  • Pregnant, breastfeeding or planning a pregnancy during the trial
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Individuals who have voluntarily agreed to participate in this clinical trial
  • Men and women aged 19 years or older at the time of providing written consent
  • Individuals who meet all of the following genetic and clinical diagnostic criteria:; Genetic diagnosis: CMT1A type; Clinical diagnosis:; Those with a CMT Neuropathy Score version 2 (CMTNSv2) between 2 or more and 20 or less; Those experiencing muscle weakness due to foot dorsiflexion impairment
  • Women and men of childbearing potential who have agreed to use the appropriate contraceptive method(s) outlined in the protocol during the clinical trial period; Appropriate contraception is defined as follows and is achieved by applying one or more methods of contraception; Hormonal contraceptives; Implantation of an intrauterine device or intrauterine system; Sterilization procedures (vasectomy, tubal ligation, etc.); Double contraceptive method: male condom along with other contraceptive methods [hormonal contraceptives (oral contraceptives, subcutaneous contraceptives (Implanon, etc.), long-acting contraceptive injections, emergency contraceptive pills), implantation of an intrauterine device or intrauterine system (Loop, Mirena), Infertility procedures (vasectomy, tubal ligation, etc.)]; Abstinence: Absolute abstinence. If, in the examiner's judgment, the subject's age, occupation, lifestyle, or sexual orientation warrants contraception, strict abstinence from sexual intercourse is also acceptable. However, periodic abstinence (e.g. Karenda method, ovulation method, symptomatic temperature method), abstinence, and external vaginal ejaculation are not recognized as appropriate contraceptive methods

Who cannot take part

  • Drugs and therapies prohibited from concurrent use; Those who participated in another clinical trial and administered/applied clinical trial drugs/medical devices within 4 weeks before screening; Those who administered/applied immunosuppressants, chemotherapy, radiation therapy, etc. within 12 weeks before screening; Persons who have administered cell therapy or gene therapy throughout their lives; Persons who have administered neurotoxic drugs that can accelerate peripheral nerve damage ① Within 1 week of Screening; Anti-inflammatory agents or antibiotics: Colchicine, Nitrofurantoin; Antiretroviral agents: Zalcitabine, Stavudine; Dichloroacetate; ② Within 55 weeks of Screening; Antiarrhythmic agent: Amiodarone; Antiparasitic agent: Suramin
  • Persons with hypersensitivity to the components of clinical investigational products
  • Medical history and surgical history; Those who have undergone orthopedic surgery (bone or ligament correction, artificial joint implantation, osteotomy, arthroscopic surgery) on the lower extremities within 24 weeks before screening; Those with a history of stroke or cerebral ischemic attack within 48 weeks before screening; Those with a history of coronary artery disease, such as myocardial infarction or incomplete angina, within 48 weeks before screening; Those with a history of malignant tumor within 240 weeks before screening (excluding basal cell carcinoma or squamous cell carcinoma that occurs on the skin)
  • Those who have had metal substances (heart pacemaker, nerve stimulator, cochlear implant, etc.) implanted in their body
  • Subjects with a psychiatric disorder (anxiety disorder, claustrophobia, or other significant mental disorder) or a history of drug and alcohol abuse that may affect the clinical trial, according to the judgment of the investigator
  • Those with the following comorbidities confirmed at the time of screening; Subjects with neuromuscular diseases other than CMT1A or neuropathy- inducing factors (uremia) that may affect the safety and efficacy evaluation of this clinical trial, according to the judgment of the investigator; Individuals diagnosed with type 1 or type 2 diabetes; Individuals diagnosed with active pulmonary tuberculosis; Patients with uncontrolled hypertension (systolic blood pressure over 180 mmHg or diastolic blood pressure over 110 mmHg); Subjects with other clinically significant diseases, including significant heart, lung, liver, kidney, hematological, immunological or behavioral diseases or malignant tumors, according to the investigator's judgment; Individuals who display the specified test abnormalities in laboratory tests at the time of screening:; AST or ALT > 3 x ULN; Total bilirubin> 1.5 x ULN; Serum creatinine > 1.5 x ULN; Any one of the serum virus tests (HBsAg, anti-HBc, anti-HCV, HIV Ag/Ab) is positive (If anti-HBc positive) However, registration is possible if the HBV DNA test result is negative. (If anti-HCV positive) However, registration is possible if the HCV RNA test result is negative; Those who have ankle contracture or have undergone surgery that may affect muscle strength measurement tests
  • Pregnant, lactating, or planning to become pregnant during the clinical trial period
  • Those who are deemed inappropriate to participate in clinical trials according to the judgment of the investigator

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Charcot-marie-tooth disease type 1A

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients with Charcot-Marie-Tooth Disease type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)

The 5 groups in the trial

  • Phase1b - Cohort 1Existing treatment, for comparison

    Phase 1b - Low dose

    Treatment: EN001

  • Phase 1b - Cohort 2Existing treatment, for comparison

    EN001 High dose

    Treatment: EN001

  • Phase 2a - Cohort 1Existing treatment, for comparison

    EN001 Low dose

    Treatment: EN001

  • Phase 2a - Cohort 2Existing treatment, for comparison

    EN001 High dose

    Treatment: EN001

  • Phase 2a - PlaceboPlacebo, for comparison

    EN001 Placebo

    Treatment: EN001 Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)
Plain-language title
Testing EN001 for Charcot-Marie-Tooth Disease Type 1AGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06328712, who can take part
Record updated
26 May 2026